Drugs / CK0804
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05423691 | Dec 2022 → Apr 2026 overdue | myelofibrosis | Cellenkos, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-30 | Incyte Corporation | Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804 incyte.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CK0804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423691 ↗ |
| Modality | Cell therapy | “CK0804 is a cryopreserved, allogeneic T-regulatory cell product” NCT05423691 ↗ |
| Route | Intravenous | “CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.” NCT05423691 ↗ |